Loading...
•
Mar 31
AbbVie Q1 2025 Earnings Report
AbbVie reported solid first-quarter results with revenue and adjusted EPS growth.
Key Takeaways
AbbVie beat expectations in Q1 2025 with strong revenue growth led by Immunology and Neuroscience, despite challenges in the Aesthetics segment.
Revenue rose 8.4% year-over-year to $13.343 billion.
Adjusted EPS grew to $2.46, supported by Immunology and Neuroscience portfolios.
Net Income was $1.286 billion, slightly down from the prior year.
Raised 2025 full-year adjusted EPS guidance to $12.09–$12.29.
AbbVie
AbbVie
AbbVie Revenue by Segment
AbbVie Revenue by Geographic Location
Revenue by Segment
Immunology Revenue
CapyFin.comNeuroscience Revenue
CapyFin.comOncology Revenue
CapyFin.comAesthetics Revenue
CapyFin.comEye Care Revenue
CapyFin.comOther Key Products Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
AbbVie raised its full-year 2025 adjusted diluted EPS guidance to $12.09–$12.29, reflecting a stronger operational outlook and successful pipeline execution.
Positive Outlook
- Raised full-year 2025 adjusted EPS guidance.
- Strong growth in Skyrizi and Rinvoq sales.
- Neuroscience portfolio posted solid gains.
- Pipeline advancements, including Rinvoq and Elahere approvals.
- Strategic investments and collaborations strengthened portfolio.
Challenges Ahead
- Aesthetics segment revenues declined significantly.
- Ongoing revenue pressure from Humira biosimilars.
- Net interest expense increased versus prior year.
- Operating margin compressed on a GAAP basis.
- Global macroeconomic uncertainties remain a risk.
Revenue & Expenses
Visualization of income flow from segment revenue to net income